SCHEMBL6316505

SCHEMBL6316505

CCC(C)NC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
APAF1 O14727 2/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
THRB P10828 2/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
RECQL P46063 2/20 0.39
BLM P54132 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317238 0.92 L3MBTL1 (0.44) RAB9AKMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL6323271 0.91 ACACB (0.37) RAB9AKMT2AMEN1L3MBTL1POLB
SCHEMBL6324905 0.91 TAS1R3 (0.42) L3MBTL1HTTALDH1A1LMNANPSR1
SCHEMBL6315860 0.89 L3MBTL1 (0.38) RAB9AL3MBTL1POLBACACBMAOB
SCHEMBL6323089 0.89 NPC1 (0.44) RAB9AKMT2AMEN1L3MBTL1HTT
SCHEMBL6316467 0.88 L3MBTL1 (0.38) L3MBTL1POLBACACBTACR3MAOB
SCHEMBL885709 0.88 SMN1; SMN2 (0.35) RAB9AKMT2AL3MBTL1POLBACACB
SCHEMBL6323394 0.87 L3MBTL1 (0.37) RAB9AKMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL6323650 0.87 KMT2A (0.47) KMT2AMEN1HTTALDH1A1GAA
SCHEMBL6317875 0.85 L3MBTL1 (0.52) KMT2AMEN1L3MBTL1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885KMT2A 1089/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.